Lixte Biotechnology launches new study in collaboration with NKI on LB-100

LIXTE Biotechnology (LIXT) announced it will conduct a new pre-clinical study in collaboration with Netherlands Cancer Institute, NKI, to test whether “initiated” cells that carry mutations found in cancer cells can be eliminated by treatment with LIXTE’s proprietary compound LB-100. “In addition to our ongoing clinical trials in ovarian and colorectal cancer, this study represents a new opportunity in cancer prevention,” said Bas van der Baan, LIXTE’s Chief Executive Officer. “Thus far in our Phase 1 clinical trials, LB-100 has shown patient tolerance, with little toxicity, making it a promising candidate as a broad and effective cancer prevention modality.”